JLE

Bulletin du Cancer

MENU

Colorectal cancers: prognostic and predictive factors of response to treatment Volume 96, issue 4, avril 2009

Authors
Service interhospitalier de cancérologie Bichat-Beaujon (SIHC), hôpital Beaujon, 100, boulevard du Général-Leclerc, 92118 Clichy, France, Département d’oncologie médicale, centre régional de lutte contre le cancer Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France, Service d’oncologie médicale, hôpital de La Pitié-Salpêtrière, 47, boulevard de l’Hôpital, 75013 Paris, France

For many years, 5-fluorouracil was the unique drug approved in the management of colorectal cancer. In the last decade, oxaliplatin, irinotecan, capecitabine and more recently targeted therapies as cetuximab and bevacizumab have been added to chemotherapy schedules. Prognosis and predictive factors are deeply needed to improve the management of the patients. To date, the TNM classification remains the only factor widely approved. But thanks to the progress of fundamental and translational research, it appears clearly that more clinical and molecular markers should be available soon to help the physician in the management of colorectal cancer.